Powerhouse Ventures Ltd. · ASX:PVL
Powerhouse Ventures — Shareholder Meeting (December 2020)
19 slides from Powerhouse Ventures's shareholder meeting presentation, Dec 21, 2020
Slide 1: Annual General Meeting 2020 Chairman's Presentation
Powerhouse Ventures Limited Annual General Meeting 2020 Chairman’s Presentation
Slide 2: Agenda
Agenda Well prepared for expansion • Update on portfolio • Australian expansion • Executing on our Business Model • Strong momentum for Science Commercialisation
Slide 3: Portfolio - Pre-seed
Portfolio Portfolio Company Company Fair Value Powerhouse amount Powerhouse Powerhouse Fair Value (NZ$’000) invested (NZ$’000) shareholding (%) (NZ$’000) (as at 30 June 2020 unless specified) Pre-seed CertusBio 1,555 366 23.53% 366 EdPotential 1,275 150 11.76% 0 Hapai 454 200 44.1% 230 1 Orbis 1,187
Slide 4: Portfolio - Seed
Portfolio Portfolio Company Company Fair Value Powerhouse amount Powerhouse Powerhouse Fair Value (NZ$’000) invested (NZ$’000) shareholding (%) (NZ$’000) (as at 30 June 2020 unless specified) Seed Auramer 3,124 250 12.68% - Avalia 5,397 460 9.68% - 2 Cirrus 10,251 150 5.9% 600 Fluent 344 570 15.39%
Slide 5: Portfolio - Post-seed
Portfolio Portfolio Company Company Fair Value Powerhouse amount Powerhouse Powerhouse Fair Value (NZ$’000) invested (NZ$’000) shareholding (%) (NZ$’000) (as at 30 June 2020 unless specified) Post-seed Croplogic 243 1,030 3.0% 0 Ferronova 4,026 631 17.1% 687 1,661 687
Slide 6: Ferronova
Ferronova Super-paramagnetic iron oxide nanoparticle (SPION) platform to improve surgical staging and therapy in solid tumour cancers Significant market opportunity and unmet need in complex cancers including the head and neck and gastrointestinal tract.
Slide 7: 2020 Progress
2020 Progress Completed $3.5m Series A Capital Raise Secured $826k BMTH3.0 Grant Funding Commenced and positive outcomes in first-in-human oral cancer trial
Slide 8: 2020 Progress (con…)
2020 Progress (con…) Pre-clinical validation in gastrointestinal indication Established US presence and appointed Chief Medical Officer Established systems for clinical trial manufacturing Strengthened board of directors Ferronova clinical trial manufacturing at GMP facility
Slide 9: Setting the new standard in vision screening & testing for everyone
SETTING THE NEW STANDARD IN VISION SCREENING & TESTING FOR EVERYONE © 2020 Objective Acuity Limited
Slide 10: The first objective vision screening and testing platform
The first objective vision screening and testing platform based on a functional vision measurement • Objective Acuity has developed objective vision tests replacing subjective tests that cannot be undertaken by young children, non-verbal people & several other groups of adults. • direct measurement
Slide 11: Objective Acuity Vision Screening Test for young children
Objective Acuity Vision Screening Test for young children • Current objective vision screening tests only assess the physical parameters of the eye 7X more accurate Objective Acuity can objectively measure how well a child is seeing Lower Cost Current tests are subjective and inaccurate in children
Slide 12: The OAL Vision Screening Test – Setup
The OAL Vision Screening Test – Setup 12
Slide 13: Inhibit Coatings
Inhibit Coatings Inhibit Coatings Limited produces leading edge antimicrobial coating using a unique silver nanoparticle functionalisation method that produces physically robust, Dr Eldon Tate Prof. Jim Johnston low-leaching and long lifetime antimicrobial coatings. CEO and Founder Founder and Direc
Slide 14: Achievements this year
Achievements this year • $1.5m capital raise January 2020 • May 2020 - $350K from NZ's COVID Innovation Acceleration Fund for development of antiviral coatings • October 2020 - Norman Barry Foundation Breakthrough Innovator Award at the 2020 KiwiNet Research Commercialisation Awards. • Jim Johnston
Slide 15: Science Commercialisation Driving Economic Recovery
Science Commercialisation Driving Economic Recovery Australia needs to diversify its economy to participate in the industries of the future by commercialising IP contained in our universities and research institutions PVL brings business skills with capital and commercialisation skills to universiti
Slide 16: Working with research teams to identify emerging commercially compelling opportunities to
Working with research teams to identify emerging commercially compelling opportunities to build companies that will attract latter stage investment capital to grow and win globally
Slide 17: Science Commercialisation – Our role
Science Commercialisation – Our role PVL targets well protected orphaned technologies in our research universities that is capable of providing a global competitive advantage • We work with the universities to establish the company to commercialise the research and accelerate those companies through
Slide 18: Critical role of government
Critical role of government Vital that the very early stage investment risk is reduced by Governments with non-dilutive capital and R&D investment support • Commercialising science benefits many beyond investors • employees • customers • competitors • universities and • Taxpayers • All advanced econ
Slide 19: Key risks
Key risks What are the key risks Company’s investments are at an early-stage and carry of investing in the inherent risk Company? Strategy risk Concentration risk Control or influence over Portfolio Companies
Powerhouse Ventures — Shareholder Meeting (December 2020) on 6ix